Tiziana Life Sciences Ltd (NASDAQ: TLSA) has announced that it will spin out its anti‑IL‑6 receptor antibody program, TZLS‑501, into a new, publicly listed company. Shareholders will receive shares in the new entity through a distribution in specie, and the transaction will be subject to shareholder approval and the new company’s compliance with listing requirements.
The spin‑out is intended to give the IL‑6 program dedicated resources while allowing Tiziana to maintain focus on its intranasal Foralumab platform, a fully human anti‑CD3 antibody in development for neuroinflammatory and neurodegenerative diseases. CEO Ivor Elrifi said the move will “unlock dedicated resources for its development, while allowing us to maintain focus on intranasal foralumab as our lead program.”
The decision follows growing industry interest in the IL‑6 pathway, highlighted by Novartis’ $1.4 billion acquisition of Tourmaline Bio’s IL‑6 inhibitor pacibekitug announced on September 9, 2025. TZLS‑501 is a fully human monoclonal antibody that blocks both membrane‑bound and soluble IL‑6 receptors, a dual mechanism that could provide a therapeutic advantage in inflammatory and oncologic indications.
Tiziana has not yet set a record date for the distribution; the company said it will announce the date in the coming weeks. Shareholder approval will be required before the spin‑out can be completed, and the new company must meet the Nasdaq listing criteria. No financial projections or valuation for the standalone IL‑6 entity have been disclosed at this time.
TZLS‑501 is being developed for a range of indications, including rheumatoid arthritis, acute respiratory distress syndrome, pulmonary fibrosis, systemic lupus erythematosus, and several solid‑tumor indications. The program’s broad disease focus reflects the expanding therapeutic potential of IL‑6 blockade across both autoimmune and oncologic markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.